MOTS - Motus GI Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8800
-0.1300 (-3.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.0100
Open3.9000
Bid1.5000 x 800
Ask4.0200 x 800
Day's Range3.8600 - 4.0356
52 Week Range2.3400 - 10.6600
Volume15,141
Avg. Volume54,004
Market Cap83.188M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.4930
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,179,202 titled, “Systems and methods for cleaning body cavities and for endoscopic steering,” which protects the Company’s flagship product, the Pure-Vu® System.

  • Business Wire10 days ago

    Motus GI to Present at the Oppenheimer 29th Annual Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will present a company overview and update at Oppenheimer’s 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 2:45 PM ET in New York, NY. A live audio webcast of the presentation will be accessible on the Events page of the Investors section on the Company’s website at www.motusgi.com.

  • Business Wirelast month

    Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “An intra-procedural endoscopic cleansing device for achieving adequate colon preparation in poorly prepped patients,” has been published in the peer-reviewed Journal of Clinical Gastroenterology.

  • Business Wire3 months ago

    Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Endoscopy Journal

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “A novel device for intra-colonoscopy cleansing of inadequately prepared colonoscopy patients – a feasibility study,” has been published in the peer-reviewed journal, Endoscopy.

  • Business Wire3 months ago

    Motus GI to Present at Biotech Showcase™ 2019

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that Tim Moran, Chief Executive Officer, will present a company overview and update at Biotech Showcase™ on Tuesday, January 8, 2019 at 4:00 PM PST in San Francisco, CA. In addition to the presentation, management will also be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. A live audio webcast of the presentation will be accessible on the Events page of the Investor section on the Company’s website at www.motusgi.com.

  • Business Wire3 months ago

     Motus GI Announces $13.5 Million Follow-on Public Offering

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the pricing of its follow-on public offering of 5,000,000 shares of its common stock at a price of $2.70 per share, for total gross proceeds of $13.5 million. In addition, the Company granted the underwriters a 30-day option to purchase an additional 750,000 shares of common stock at the public offering price. Piper Jaffray & Co. is acting as the sole book-running manager for the offering.

  • Business Wire3 months ago

    Motus GI Announces Launch of Proposed Follow-on Public Offering

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed follow-on public offering of 5,000,000 shares of its common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase an additional 750,000 shares of common stock.

  • What Kind Of Shareholder Appears On The Motus GI Holdings Inc’s (NASDAQ:MOTS) Shareholder Register?
    Simply Wall St.4 months ago

    What Kind Of Shareholder Appears On The Motus GI Holdings Inc’s (NASDAQ:MOTS) Shareholder Register?

    A look at the shareholders of Motus GI Holdings Inc (NASDAQ:MOTS) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see Read More...

  • Business Wire4 months ago

    Motus GI to Present at the Piper Jaffray Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Tim Moran, Chief Executive Officer, will provide a corporate overview during a fireside chat at the Piper Jaffray Healthcare Conference on Thursday, November 29, 2018 at 10:00 a.m. EST in New York, NY.

  • GlobeNewswire4 months ago

    Orchestra BioMed™ Announces Completion of $41 Million Financing

    Capital proceeds to support late-stage clinical development of lead cardiovascular product candidates for artery disease and hypertension        Financing structure provides.

  • Business Wire4 months ago

    Motus GI Reports 2018 Third Quarter Financial Results and Provides Business Update

    Third quarter featured strengthening of executive team with proven commercial leadership, building additional clinical and health economic evidence demonstrating potential value of

  • Business Wire4 months ago

    Motus GI Announces Successful Clinical Use of Pure-Vu® Slim Sleeve with Slim Colonoscopes

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the first successful clinical cases were completed in late October with the Company’s Pure-Vu® Slim Sleeve, a compatible extension to the Pure-Vu® System for slim colonoscopes. The Company recently announced that the Pure-Vu® Slim Sleeve had received special 510(k) clearance from the U.S. Food and Drug Administration (FDA).

  • Business Wire5 months ago

    Motus GI Presents Positive Clinical Data from U.S. Prospective Study of the Pure-Vu® System at the 2018 American College of Gastroenterology (ACG) Annual Meeting

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that it presented positive clinical data at the ACG 2018 Annual Meeting being held October 5-10, 2018 in Philadelphia, PA.

  • Business Wire6 months ago

    Motus GI to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Mark Pomeranz, President and COO of Motus GI, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 3:00 p.m. EDT in New York, NY. As part of his presentation, Mr. Pomeranz will provide a corporate overview, along with an update on the current pre-launch, market development activities and ongoing REDUCE clinical study of the Company's flagship product, the Pure-Vu® System.

  • Business Wire6 months ago

    Motus GI Appoints Medical Device Commercial Leader Timothy P. Moran as Chief Executive Officer; Mark Pomeranz Continues in Key Executive Leadership Role as President and Chief Operating Officer

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that Timothy P. Moran will assume the role of Chief Executive Officer and member of the Board of Directors on October 1, 2018. Mr. Moran will join Motus GI from ConvaTec Group Plc (CTEC.L) where he has served as President of the Americas since 2015.

  • Is Motus GI Holdings Inc’s (NASDAQ:MOTS) Balance Sheet A Threat To Its Future?
    Simply Wall St.6 months ago

    Is Motus GI Holdings Inc’s (NASDAQ:MOTS) Balance Sheet A Threat To Its Future?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Motus GI Holdings Inc (NASDAQ:MOTS), as the company does not have to adhere to strict debt covenants. However, it alsoRead More...

  • Business Wire6 months ago

    Motus GI Receives FDA Clearance to Market Pure-Vu® Slim Sleeve for Use with Slim Colonoscopes

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that it has received special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Pure-Vu® Slim Sleeve, a compatible extension to the Pure-Vu® System for slim colonoscopes.

  • Business Wire7 months ago

    Motus GI Reports 2018 Second Quarter Financial Results and Provides Business Update

    – Building clinical and health economic evidence demonstrating potential value of the Pure-Vu® System in high need patient populations with focus on inpatient colonoscopy market –

  • Business Wire7 months ago

    Motus GI Appoints Jeff Hutchison as VP of U.S. Sales and Commercial Operations

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today the appointment of Jeff Hutchison as Vice President of U.S. Sales and Commercial Operations. Mr. Hutchison will be responsible for building Motus GI’s U.S. sales organization and driving the Company’s pre-launch commercial activities ahead of the planned launch of the Pure-Vu® System into the inpatient market in 2019.

  • Business Wire8 months ago

    Motus GI Strengthens IP Portfolio with Issuance of Japanese Patent for the Pure-Vu® System

    Motus GI Holdings, Inc., (MOTS) (“Motus GI” or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that the Japanese Patent Office has issued a patent covering claims related to the Company’s flagship product, the Pure-Vu® System, a medical device that cleanses the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure to enable a quality exam and has demonstrated effective cleaning in hundreds of procedures. “The need to improve the quality, efficiency and cost-effectiveness of inpatient colonoscopy procedures is a global issue. While our immediate focus continues to be on market development and preparation for commercial launch of the Pure-Vu® System for inpatient colonoscopy in the U.S., we believe Japan is a key international market for future commercial expansion,” commented Mark Pomeranz, CEO of Motus GI.

  • Business Wire9 months ago

    Motus GI Announces Inclusion in the Russell Microcap® Index

    Motus GI Holdings, Inc., (MOTS) (“Motus GI” or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it was added to the Russell Microcap® Index at the conclusion of the Russell indexes annual reconstitution on June 22, 2018.

  • Business Wire10 months ago

    Motus GI Presents Cost Analysis Data Demonstrating Pure-Vu® System Has the Potential to Reduce Costs and Incidence of Colorectal Cancer at Digestive Disease Week® 2018

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes, costs and quality of care, today announced that data from a cost-minimization analysis simulating the average lifetime costs and incidence of new colorectal cancer (CRC) comparing colonoscopy using Motus GI’s Pure-Vu® System versus standard colonoscopy (SC) alone were presented by Professor Ian M. Gralnek, MD, MSHS, FASGE, at Digestive Disease Week® 2018 (“DDW”), on June 2, 2018.

  • Business Wire10 months ago

    Motus GI Enrolls First Patient in REDUCE Study of the Pure-Vu® System in Hospitalized Patients

    Motus GI Holdings, Inc., (MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving endoscopy outcomes and experiences, announced today that it has enrolled the first patient in its REDUCE (Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement) study. The REDUCE study is a single-arm multi-center, prospective study that will utilize the Pure-Vu® System to facilitate bowel cleansing in approximately 100 hospitalized patients who are indicated for a diagnostic colonoscopy procedure. The Pure-Vu® System is a medical device that cleans the colon intra-procedurally to facilitate improved visualization during a colonoscopy procedure to enable a quality exam and has demonstrated effective cleaning in hundreds of procedures.